Events

AusBiotech and ANDHealth partner to foster sector connection in digital health May 5, 2025

AusBiotech has signed a partnership agreement with digital health commercialisation specialist ANDHealth to enhance collaboration on mutual interests and support ongoing industry innovation.

Neurotech says NTI164 shows positive tolerability in key preclinical toxicology studies May 5, 2025

Neurotech International (ASX:NTI) has announced positive results from its recently completed 28-day Good Laboratory Practice oral toxicology studies evaluating its lead drug candidate NTI164.

Arovella options advances Baylor College of technology to enhance iNKT cell platform May 5, 2025

Arovella Therapeutics (ASX:ALA) has entered into an exclusive option to license multiple patent families from Baylor College of Medicine to broaden the utility and enhance the performance of its iNKT cell platform.

FDA grants fast track designation for Alterity's ATH434 to treat multiple system atrophy May 5, 2025

Alterity Therapeutics (ASX:ATH) has announced that the US FDA has granted fast track designation for ATH434 for treating Multiple System Atrophy.

Positive trial result for Immutep’s 'efti' in combination with MSD's anti-PD-1 therapy May 5, 2025

Immutep (ASX:IMM) has announced positive results from a Phase 2b trial of its eftilagimod alfa (efti) in combination with MSD's KEYTRUDA (pembrolizumab) for head and neck cancer.

Medtech investment event unites investors and innovators to boost sector growth May 5, 2025

AusBiotech CEO Rebekah Cassidy said the investor-focused event will help accelerate the delivery of real-world, home-grown health solutions.

Dimerix secures exclusive US licence agreement with Amicus Therapeutics May 1, 2025

In one of the largest licensing deals in the Australian biotechnology industry, Dimerix (ASX:DXB) has signed an exclusive US licence agreement with Amicus Therapeutics to commercialise its kidney disease drug candidate DMX-200.

AdAlta announces renounceable rights issue to raise up to $1.3 million May 1, 2025

Cell therapy company AdAlta (ASX:1AD) is undertaking a two-for-three renounceable rights issue at 0.3 cents per share to raise up to approximately $1.3 million.

Race Oncology confirms successful and safe dosing of first patient in Phase 1 solid tumour trial May 1, 2025

Race Oncology (ASX:RAC) has announced the successful and safe dosing of the first patient with RC220 in its Phase 1 clinical trial in advanced solid tumours.

BlinkLab capital raise to advance AI-powered diagnostics for autism and ADHD trials May 1, 2025

Digital health company BlinkLab (ASX:BB1) has completed a placement to both domestic and international sophisticated and institutional investors, raising $7.66 million before costs at $0.30 per share.

IDT reports significant growth for the March quarter April 29, 2025

Contract pharmaceutical manufacturer IDT Australia (ASX:IDT) has announced a 30.4 per cent increase in revenue growth for the three months ending March 2025.

Dimerix says FDA confirms proteinuria as acceptable endpoint for DMX-200 Phase 3 trial April 29, 2025

Dimerix (ASX:DXB) has provided an update on its ACTION3 Phase 3 clinical trial of DMX-200 in a rare kidney disease, Focal Segmental Glomerular Sclerosis.

Most Read

Arovella options advances Baylor College of technology to enhance iNKT cell platform

Medtech investment event unites investors and innovators to boost sector growth

Positive trial result for Immutep’s 'efti' in combination with MSD's anti-PD-1 therapy

AusBiotech and ANDHealth partner to foster sector connection in digital health

FDA grants fast track designation for Alterity's ATH434 to treat multiple system atrophy

New Stories

AusBiotech and ANDHealth partner to foster sector connection in digital health

Neurotech says NTI164 shows positive tolerability in key preclinical toxicology studies

Arovella options advances Baylor College of technology to enhance iNKT cell platform

FDA grants fast track designation for Alterity's ATH434 to treat multiple system atrophy

Positive trial result for Immutep’s 'efti' in combination with MSD's anti-PD-1 therapy

Medtech investment event unites investors and innovators to boost sector growth

BlinkLab capital raise to advance AI-powered diagnostics for autism and ADHD trials

Sign In

Most Read

Arovella options advances Baylor College of technology to enhance iNKT cell platform

Medtech investment event unites investors and innovators to boost sector growth

Positive trial result for Immutep’s 'efti' in combination with MSD's anti-PD-1 therapy

AusBiotech and ANDHealth partner to foster sector connection in digital health

FDA grants fast track designation for Alterity's ATH434 to treat multiple system atrophy

Follow Us

New Stories

AusBiotech and ANDHealth partner to foster sector connection in digital health

Neurotech says NTI164 shows positive tolerability in key preclinical toxicology studies

Arovella options advances Baylor College of technology to enhance iNKT cell platform

FDA grants fast track designation for Alterity's ATH434 to treat multiple system atrophy

Positive trial result for Immutep’s 'efti' in combination with MSD's anti-PD-1 therapy

Medtech investment event unites investors and innovators to boost sector growth

BlinkLab capital raise to advance AI-powered diagnostics for autism and ADHD trials